Method for treating gastric disorders using optically pure (−) pantoprazole
US6953808B2 · kind B2 · utility
5Cited by
2References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 14, 2004 |
| Grant date | Oct 11, 2005 |
| Priority date | — |
| Expiry date | Feb 17, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are disclosed utilizing optically pure (−) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Pantoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.